

Learner Notification

MED Learning Group

Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers

November 28, 2023 – November 28, 2024

Online

Acknowledgement of Financial Commercial Support

Lilly

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers.
2. Select appropriate second- and subsequent-line therapy for the management of gastric/GEJ cancers.
3. Assess clinical trials findings in patients who could benefit from anti-angiogenic treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers.
4. Apply clinical practice guidelines for second treatment in patients with advanced and metastatic gastrointestinal cancers to maximize patient outcomes through proper sequencing of therapy.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Lauren	Bartunek	NA
Thomas	Cartwright	NA
Efrat	Dotan	Olympus, Amgen, Pfizer, G1 Therapeutics, Taiho Pharma, Incyte, Helsinn Healthcare: Consultant, Zymeworks, Lutris, NGM Biopharmaceuticals, Ipsen, Gilead: Contracted Research
Richard F.	Dunne	Exelixis, Toray Industries, Helsinn Healthcare, Merck: Consultant
Matthew	Frese	NA
Christina	Gallo	NA
Heather	Gee	NA
Samuel	Klempner	Astellas, Merck, Novartis, Pfizer, BMS, AstraZeneca, Daiichi-Sankyo, Sanofi-Aventis, Servier, Mersana, Exact Sciences, Amgen: Consultant, Turning Point Therapeutics, Nuvalent Therapeutics: Stock Shareholder

Nicole	Longo	NA
Aimee	Meissner	NA
Chimene	Richa	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com